论文部分内容阅读
目前国内的大型制药企业非常多,除了综合的大型制药企业及以某种主导产品为龙头的特色型企业外,另外还有一种,以厦门迈克和上海迪赛诺为代表,它们均以目前国内生产抗艾滋病药而闻名,但是实际上,它们却并不靠抗艾药盈利。它们均以外贸起家,在海外市场,早已有较大的市场占有率及知名度,也因此,加入WTO后,面对辉瑞、葛兰素史克、施贵宝、默沙东等国际制药巨头的竞争压力,它们却表现出了少见的从容镇定,这其中,当然自有缘由。
At present, there are a lot of large-scale pharmaceutical enterprises in China. Apart from a large-scale pharmaceutical enterprise and a featured enterprise with leading products, there is another kind, represented by Xiamen Mike and Shanghai Di Sino, Known for its production of anti-AIDS drugs, in fact, they are not profitable by anti-AIDS drugs. All of them started out in foreign trade and already have a large market share and popularity in overseas markets. Therefore, after joining WTO, facing the competitive pressures of international pharmaceutical giants like Pfizer, GSK, Squibb and Merck, Showing a rare calm calm, of which of course there are its own reasons.